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Abstract
Background: In Norway, repeat cytology and HPV testing comprise delayed triage of women with minor cytological lesions.
The objective of this study was to evaluate HPV DNA and HPV mRNA testing in triage of women with an ASC-US/LSIL
diagnosis.
Materials and Methods: We used repeat cytology, HPV DNA testing (Cobas 4800) and HPV mRNA testing (PreTect HPV-
Proofer) to follow up 311 women aged 25–69 years with ASC-US/LSIL index cytology.
Results: Of 311 women scheduled for secondary screening, 30 women (9.6%) had ASC-H/HSIL cytology at triage and 281
women (90.4%) had ASC-US/LSIL or normal cytology. The HPV DNA test was positive in 92 (32.7%) of 281 instances, and 37
(13.2%) were mRNA positive. Of the 132 women with repeated ASC-US/LSIL, we received biopsies from 97.0% (65/67) of the
DNA-positive and 92.9% (26/28) of the mRNA-positive cases. The positive predictive values for CIN2+ were 21.5% (14/65) for
DNA positive and 34.6% (9/26) for mRNA positive (ns). The odds ratio for being referred to colposcopy in DNA-positive cases
were 2.8 times (95% CI: 1.8–4.6) higher that of mRNA-positive cases. Compared to the mRNA test, the DNA test detected
four more cases of CIN2 and one case of CIN3.
Conclusions: The higher positivity rate of the DNA test in triage leads to higher referral rate for colposcopy and biopsy, and
subsequent additional follow-up of negative biopsies. By following mRNA-negative women who had ASC-US/LSIL at triage
with cytology, the additional cases of CIN2+ gained in DNA screening can be discovered. Our study indicates that in triage
of repeated ASC-US/LSIL, HPV mRNA testing is more specific and is more relevant in clinical use than an HPV DNA test.
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Introduction
The goal in primary screening for cervical cancer is to detect
and treat high-grade cervical intraepithelial lesions before invasive
cancer develops [1]. In Norway, a cervical cancer screening
program was introduced in 1995, recommending all women
between 25 and 69 years of age to have a cytological cell sample
(Pap-smear) collected every third year [2]. The Norwegian cervical
cancer program recommends secondary screening with repeat
cytology and an HPV test 6–12 months after the index diagnosis of
an atypical squamous cell of undetermined significance (ASC-US)
or low-grade squamous intraepithelial lesions (LSIL). Women with
high-grade squamous intraepithelial lesions (HSIL) or ASC-US/
LSIL with a positive HPV outcome are referred to colposcopy/
biopsy immediately after triage. Women with a normal smear and
a positive HPV test are recommended a repeat HPV test within 12
months, whereas women with an ASC-US/LSIL/normal smear
with a negative HPV test are returned to the screening program at
a three-year interval.
In Norway, cytological high-grade lesions are detected in 1.0–
1.2% in each screening round of the national cervical cancer
screening program [3]. The major challenge in any cervical cancer
screening program is the management of minor cervical lesions
such as ASC-US and LSIL [4]. Women with minor cervical
lesions comprise a 4-fold volume of tests/visits for the health care
system in comparison to women with high-grade cervical lesions
[3]. In cytology-based screening several strategies have been
assessed for women with minor cervical lesions, in combination
with testing for human papilloma virus (HPV). One strategy is
direct referral to colposcopy and biopsy in women with ASC-US/
LSIL [5]. In reflex testing, women with ASC-US/LSIL are
examined with an HPV test in the index cytology specimen, and
positive cases are referred directly to colposcopy [6,7]. A third
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strategy is repeat cytology after 6–12 months, while a fourth
strategy is repeat cytology/HPV testing 6–12 month after primary
ASC-US/LSIL diagnosis (delayed HPV triage) [8]. It is also
possible to triage women with minor cervical lesions by HPV 16/
18 genotyping or via biomarkers such as HPV E6/E7 mRNA,
p16/Ki67, methylation and ProEx C [9–16].
In the ASC-US/LSIL triage study (ALTS) women were
randomized to repeat cytology, direct referral to colposcopy or
HPV triage [6,7,17]. After two years of follow-ups, there were no
differences in detection rates of CIN3+ between the study arms.
The HPV triage arm referred about half as many women to
colposcopy as those with direct referral in ASC-US cases. Women
with repeat cytology required at least two follow-ups leading to
more colposcopic examinations than in the HPV arm [6,7,17]. In
the ALTS study the prevalence of oncogenic HPV was too high
(85%) to permit effective triage of LSIL using HPV DNA testing.
Thus immediate referral to colposcopy was advocated for these
women [17].
As only a small proportion (8–12%) of women with ASC-US or
LSIL harbor high-grade histologically confirmed disease (CIN2+)
[6–8,17,18], a test with high specificity would be desirable in
secondary screening to avoid too many referrals to colposcopy
[19]. Although HPV infection is a necessary factor in carcino-
genesis, the majority of HPV infections are transient even in
women with CIN2 after an ASC-US/LSIL diagnosis [20]. In
general, HPV DNA tests generate more positive results than the
HPV E6/E7 mRNA test [21]. This is because DNA tests detect
the presence of the virus and will therefore also detect harmless
transient infections, which are handled by the immune system,
along with lesion regression [10]. The real cause of cervical cancer
is not the HPV virus infection per se, but continuous over-
expression of the viral oncogenes E6 and E7 from oncogenic HPV
types [22]. Consequently, testing for the presence of HPV DNA is
associated with a relatively low risk for underlying high-grade
histological-confirmed intraepithelial lesion, even in women with
ASC-US/LSIL [4].
In this study we performed a direct comparison of an HPV
mRNA and an HPV DNA test in secondary screening of ASC-
US/LSIL related to referral rates for colposcopy, biopsy rates,
histological outcomes and sojourn time back to the screening
program.
Results
For most women (81%) the index cytology represented the first
ASC-US/LSIL diagnosis, whereas 10% and 9% of the women
had a history of one or two to five ASC-US/LSIL diagnoses,
respectively. The positivity rate of the HPV DNA test was 36.7%
(114/311) relative 18.3% (57/311) for the HPV mRNA test
(Table 1).
Thirty of the 311 women had ASC-H/HSIL cytology at triage,
and 22, 20 and 8 of the ASC-H/HSIL cases were HPV DNA
positive, HPV mRNA positive and HPV DNA/mRNA double
negative, respectively. All 20 HPV mRNA positive cases were
DNA positive. Among ASC-US/LSIL cases at triage, 68 were
HPV positive for one or both tests: 27 were double positive
(DNA+/mRNA+), 40 were DNA+/mRNA- and one woman was
DNA-/mRNA+.
A total of 281 women (90.4%) had ASC-US, LSIL, normal or
inconclusive cytology at triage. Of these 281 women, 92 (32.7%)
were HPV DNA positive and 37 women (13.2%) were HPV
mRNA positive (Table 2). Among these 281 women, 16 were
positive for HPV type 16 (DNA and/or mRNA), 15 for HPV
DNA and 14 for HPV mRNA. Similar estimates for nine HPV
type 18 positive women (HPV 16 negative) were seven and six for
HPV DNA and HPV mRNA, respectively. Most discordant pairs
were seen for other HPV types (HPV 16 and 18 negative), where
70 out of 71 were HPV DNA positive, relative to 17 HPV mRNA-
positive women (Table 2).
The status at triage by diagnostic test are displayed in Table 3.
The direct referral rate to colposcopy/biopsy were 24% using
HPV DNA test respective 10% using HPV mRNA test (p,0.001).
Within 12 months after triage, 65 out of 67 HPV DNA positive
had met for biopsy respective 26 out of 28 in the HPV mRNA
group (Table 4).
The positive predictive values for CIN2+ were 21.5% (14/65)
for DNA positive and 34.6% (9/26) for mRNA positive. The
positive predictive values for CIN3+ were 6.2% (4/65) for DNA
positive and 11.5% (3/26) for mRNA positive. The odds ratio
(OR) for being referred to colposcopy were 2.8 (95% CI: 1.8–4.6)
in the HPV DNA group compared with the HPV mRNA group.
The increased referral rate resulted in an additional diagnosis of
four more cases of CIN2 and one more case of CIN3.
Since we used the HPV DNA as a reference test, the sensitivity
of the HPV DNA test is 100% (14/14) relative 64.3% (9/14, 95%
CI: 39.2–89.4) for the HPV mRNA test. The corresponding
estimates of specificity are 70.8% (189/267, 95% CI: 65.5–76.3)
and 89.5% (239/267, 95% CI: 85.8–93.2).
Discussion
Our study shows that HPV mRNA is more specific than HPV
DNA in triage of women with repeated ASC-US/LSIL. A low
positivity rate translates into a low referral rate for colposcopy,
which is very appealing for triage situations. The referral rate for
colposcopy was significantly higher for HPV DNA positive relative
to HPV mRNA positive, winning only four more cases of CIN2
and one more case of CIN3. Thus, compared with the mRNA test,
the use of DNA tests in triage more than doubled the workload for
gynecologists and laboratories. As long as women with repeated
ASC-US/LSIL and negative HPV mRNA tests are followed up
Table 1. Cytology at triage by HPV test positivity.
Cytology at triage Number HPV DNA pos HPV mRNA pos
Normal 142 25 (17.6) 9 (6.3)
Inconclusive 7 0 (0.0) 0 (0.0)
ASC-US/LSIL 132 67 (50.8) 28 (21.2)
ASC-H/HSIL 30 22 (73.3) 20 (66.7)
Total 311 114 (36.7) 57 (18.3)
doi:10.1371/journal.pone.0112934.t001
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with a new cytology after 12 months, very few cases of CIN2+
captured by DNA at triage will be lost [8,18].
The higher specificity of the HPV mRNA test translates into 39
more direct referrals to colposcopy/biopsy after ASC-US/LSIL
diagnosis and positive HPV DNA and negative HPV mRNA.
Among these women, four cases of CIN2 and one case of CIN3
were diagnosed, in addition to 20 extra cases of CIN1 and 14 extra
cases with normal histology (Table 4). All women with negative
biopsies (normal/CIN1) need further follow-ups because of limited
sensitivity of colposcopy/biopsy [23,24]. The choice of test
represents a trade-off between benefits (detected CIN2+), which
are greater for HPV DNA test, and harms (unnecessary
colposcopies/biopsies), which are smaller for HPV mRNA test.
The HPV DNA test has higher sensitivity for CIN2+ than the
HPV mRNA test. Women with repeated ASC-US/LSIL and a
negative HPV mRNA test cannot be considered free of CIN2+
and need follow-up with another smear within 12 months. In two
recently published studies from Norway, this is also the case for
women with a negative HPV DNA test in delayed triage of ASC-
US/LSIL [8,25]. As the data from the Norwegian cancer registry
are complete from all cytology laboratories, the practice of
following up HPV DNA negative cases of repeated ASC-US/LSIL
is nationwide despite lack of national guideline of this practice
[8,25].
Several studies have compared performance of different HPV
diagnostic tests in direct referral to colposcopy after an abnormal
cytology of repeated borderline/mild dyskaryosis or worse [26,27].
In the Predictors 2 study, colposcopy-negative women were
considered free of intraepithelial cervical disease. In a subset of
670 women with mild or repeated borderline smears, Cobas 4800
had a sensitivity and specificity for CIN3+ of 100.0% and 23.0%,
respectively, versus 80.9% and 67.9% for the mRNA PreTect
HPV-Proofer test. If we apply these estimates to the Norwegian
setting of delayed triage, an additional 296 colposcopies had to be
performed using Cobas 4800 for winning 24 cases of CIN2 and 9
cases of CIN3, in comparison with the HPV mRNA test. In direct
referral studies, the use of health resources is not considered an
issue of unnecessary referrals nor an issue of overtreatment of
CIN2 lesions that regress spontaneously [5,20].
At the time of recruitment of Predictors 2 study, there were no
guidelines for HPV testing. In 2010 the British recommendations
implemented HPV testing in triage of women with borderline and
mild dyskaryosis (reflex testing). Women with a negative HPV test
are returned to screening. Women with a positive HPV test, but a
normal colposcopy without having any biopsies collected, are also
returned to screening. This is not the case in Norway. The
Norwegian guidelines recommend follow-up of women with a
negative cervical biopsy (www.kreftregisteret.no).
Within the British health care system all women with mild
dyskaryosis or worse are referred to colposcopy. In Norway most
of the cervical samples are collected by the general practitioner.
The Norwegian health care system has limited resources allocated
to colposcopy/biopsy. In Norway, the HPV test in delayed triage
of women with ASC-US/LSIL index cytology is used to select
women with a higher risk of CIN2+, thus reducing the number of
referrals [8,25,28,29].
Colposcopies are costly procedures and can cause psychological
stress [30]. Histopathologic diagnoses of CIN1 and CIN2 in
cervical biopsies are prone to poor inter-observer reproducibility
[12,31], and a high referral rate for colposcopy and a high biopsy
rate will inevitably result in some degree of overtreatment
[20,32,33]. Furthermore, conization increases the risk of prema-
ture birth and late abortions in subsequent pregnancies [34–36]. A
reduced rate of referral to colposcopy will reduce the costs to the
Table 2. Concordance between HPV mRNA and HPV DNA types.
Triage test HPV DNA
HPV mRNA Negative HPV 16* HPV 18** HPV Others*** Total
HPV mRNA negative 186 2 3 53 244
HPV mRNA 16* 0 13 0 1 14
HPV mRNA 18** 2 0 4 0 6
HPV mRNA Others*** 1 0 0 16 17
Total 189 15 7 70 281
*HPV 16 and all other types.
**HPV 18, all other types except for HPV 16.
***All other types, except for HPV 16 and/or 18.
doi:10.1371/journal.pone.0112934.t002
Table 3. Status of triage by HPV-test.
Triage outcome HPV DNA HPV mRNA
Return to screening* 124 (44.1) 140 (49.8)
Follow-up by cytology** 90 (32.0) 113 (40.2)
Colposcopy/biopsy*** 67 (23.8) 28 (10.0)
Total 281 (100.0) 281 (100.0)
*Normal/inconclusive cytology and HPV negative.
**Normal and HPV positive or ASC-US/LSIL and HPV negative.
***ASC-US/LSIL and HPV positive.
doi:10.1371/journal.pone.0112934.t003
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health care system, reduce overtreatment, reduce the negative
impact of cervical treatment on pregnancy outcomes and reduce
psychological stress for the women.
The strengths of this study are the direct comparison of clinical
usefulness of two different HPV diagnostic tests applied in an
unselected population within a national screening program. The
study population is one with a low-risk of CIN2+, as none had
HSIL or a diagnosis of CIN/ACIS or worse, and 19% of the
women had a history of ASC-US/LSIL before index cytology.
We consider the small sample size (N = 311) and insufficient
follow-up time in the cytology arm as limitations of our study.
According to the Norwegian guidelines, women with normal
cytology and a positive HPV result at triage should be followed up
with a new cytology and HPV test within 12 months after triage.
According to the Norwegian guidelines, women with repeated
ASC-US/LSIL and a negative HPV result are returned to
screening even though the risk of CIN2+ is more than 2.0%
[8,18,25]. Our hospital recommends follow-up within 12 months
of these women [18]. Because of limited follow-up time, we have
incomplete numbers of biopsies in this subgroup.
The Norwegian follow-up strategy for ASC-US/LSIL reflects
the natural history of duration of primary HPV 16/18 infections/
lesion formation, as there is a 6–12 month window before triage is
undertaken [37]. The most recent cytology was normal for all
women before index ASC-US/LSIL. Therefore we consider the
index cytology as a consequence of a primary HPV infection or a
re-infection in women who have demonstrated clearance of HPV
infections in the past. The interval from index ASC-US/LSIL to
triage is a necessary time period for giving the immune systems an
opportunity to clear the lesion [20]. This is especially important
among younger women [38–41]. Study designs that practice reflex
testing or immediate referral to colposcopy do not take the natural
history of HPV infections/lesion formation into consideration and
will diagnose and treat more lesions that otherwise will regress
spontaneously [20,42].
There is a trade-off in any screening program how to find the
most efficient way of diagnosing the long standing CIN2+ which
have the potential to progress to cervical cancer. HPV type 16 in
particular, HPV 18 and HPV 45 have demonstrated the highest
progression rates to CIN3 and cervical cancer over a 10–20 year
perspective [43–47]. The concordance between the DNA test and
the mRNA test diagnosing HPV 16 and HPV 18 infections was
highly acceptable in this study. The discrepancy in HPV detection
rates between the diagnostic tests were other HPV types, which
have a much lower potential to progress to cervical cancer over the
next decades. Therefore it is most important to diagnose CIN2/3
lesions specific to HPV 16, 18 and 45 as these lesions may progress
faster to cancer [46,47]. Even though less oncogenic high-risk
HPV types are identified within cervical cancer, some data suggest
the these HPV types have the potential to initiate the normal cell
to progress to CIN2/3, and question the less oncogenic high-risk
types’ capacity to progress further from CIN into cervical cancer
[48,49].
Participation in a screening program is voluntarily. If there are
too many ‘‘false’’ alerts, the program will lose legitimacy among
women, which again may lead to lower attendance rates. In this
respect we consider high specificity to be more important than
high sensitivity in overall CIN2/3 detection. Within the referral
algorithm for the Norwegian cervical cancer program, our study
shows that the referral rate to colposcopy was more than doubled
for the DNA versus the mRNA tested women, and the sojourn rate
back to regular screening was significantly higher. The importance
of a screening program is to treat the women in such a way that
they remain confident in the program and continue attendance.
So far these issues have not been discussed from the point of view
of medicine, societal costs, ethics or women. There is a need for
additional studies on head-to-head comparison of HPV tests in
both primary and secondary screening that target different
molecular sites.
Materials and Methods
The Regional Committee for Medical and Health Research
Ethics, Northern Norway, approved the study as a quality
assurance study in laboratory work fulfilling the requirements for
data protection procedures within the department (REK Nord
2012/276). Written consent from the patients for their information
to be stored in the hospital database and used for research was not
needed because the data were analyzed anonymously. The ethics
committee specifically waived the need for consent.
Our study contains two different HPV tests to triage women
with minor cervical lesions: the HPV mRNA test PreTect HPV-
Proofer (NorChip AS), which detects E6/E7 mRNA (encoding the
viral oncoproteins) of 5 HPV types, and the HPV DNA test Cobas
4800 (Roche), which detects 14 HPV types.
The HPV DNA test Cobas 4800 is designed as a qualitative
single tube multiplex assay based on the real time PCR technology
that simultaneously detects 14 high-risk genotypes. The assay
identifies HPV type 16 and 18 with concurrent detection of twelve
other HPV types (HPV-31, -33, -35, -39, -45, -51, -52, -56, -58, -
59, -66, -68) using L1 primers, and ß-globin is used as an internal
control. DNA is isolated from a scrape of cells from a woman’s
cervix and is subsequently mixed in reaction wells with primers
and probes that specifically recognize and amplify HPV DNA.
This reaction produces fluorescence, which is then measured to
determine the presence of HPV in the cervical sample. Specialized
pipetting technology combined with AmpErase enzymes reduces
cross contamination risk (http://www.roche.com).
The HPV mRNA test PreTect HPV-Proofer is an E6/E7
mRNA-based real-time nucleic acid sequence-based amplification
Table 4. Most severe histology of biopsies/cone specimen by screening test.
Histology HPV DNA HPV mRNA
Normal 19 (29.2) 5 (19.2)
CIN1 32 (49.2) 12 (46.2)
CIN2 10 (15.4) 6 (23.1)
CIN3 4 (6.2) 3 (11.5)
Total* 65 (100.0) 26 (100.0)
*Two of the HPV DNA positive and two of the HPV mRNA positive women with ASC-US/LSIL did not meet for colposcopy/biopsy.
doi:10.1371/journal.pone.0112934.t004
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assay (NASBA), focusing on the reportedly most common
oncogenic HPV types 16, 18, 31, 33 and 45 using specific E6/
E7 primers for each HPV-type. To avoid false negatives due to
degradation of mRNA, primers and probes against human U1A
mRNA are included in the PreTect HPV-Proofer kit as a
performance and integrity control. Artificial oligonucleotides
corresponding to the viral mRNA were used as positive controls.
Negative controls consisted of Rnase-free water and were included
in each run (http://www.norchip.com/).
We extracted cervical cells from the LBC by the ThinPrep 2000
(Cytyc Corporation, Marlborough, MA, USA) for cytological
examination. DNA/RNA was isolated from 5 ml of the leftover
material and analyzed with PreTect HPV-Proofer. The mRNA
testing was performed according to the manufacturer’s instructions
(NorChip AS). The HPV DNA testing (Roche Cobas 4800) was
performed and in accordance with national guidelines for HPV
testing [28]. We defined the HPV DNA test as the reference in the
study.
Our department analyses annually 23 000 cervical cytology
samples. Between January 1st, 1991, and March 31, 2013, 98 579
female residents were reported at the county level, with 494 400
valid cervical smears in the clinical database SymPathy. Within
this database we identified 2394 women with at least one ASC-
US/LSIL diagnosis from January 1st, 2010, through September
30th, 2012. After excluding women who had at least one HSIL
diagnosis (n = 326) or cervical biopsy referral (n = 294) prior to
index ASC-US/LSIL diagnosis, women who were 15–24 (n = 271)
or 70–91 (n = 20) years of age at index ASC-US/LSIL, 1523
women were eligible for analysis. Furthermore, we excluded
women with no follow-up (n = 199), who had direct biopsy
(n = 79), who had triage less than 3 months (n = 65) or more than
18 months (n = 20) after index ASC-US/LSIL. After these
exclusions 1169 women within the age span of the Norwegian
cervical screening program and who had no prior HSIL or
cervical biopsy constituted the preliminary study population.
Our study began on January 1st, 2012, at which time our
department switched from HPV mRNA testing to HPV DNA
testing in secondary screening of ASC-US/LSIL. Included were
women who had their index ASC-US/LSIL cytology back in 2010
because of varying intervals in scheduled follow-ups. Our protocol
expanded the time window and included all women who had a
diagnosis ASC-US/LSIL over the last 3 to 18 months, different
from the national screening program’s recommended 6–12 month
interval [8]. In the transition period to HPV DNA testing, our
department only conducted cytology follow-ups in cases with
sparse material in the cytology specimen or HPV mRNA testing
when enough material was present. After excluding 376 women
who were followed up with cytology only, and 482 women who
had cytology and mRNA follow-ups only, our study population
comprised 311 of 1169 eligible women who had cytology, mRNA
and HPV DNA tests at triage. Outcome assessment was based on
the histological result of biopsies, where CIN2+ was considered as
the target disease and CIN1 and CIN0 (no CIN) were considered
as absence of disease. Moreover, women with double negative
liquid-based cytology (LBC) and HPV mRNA result were assumed
to be free of disease. All women were followed through September
31, 2014 for end points.
All statistical analyses used SPSS version 21 to perform Chi-
square tests, Mann-Whitney tests and survival analysis. A p-value
,0.05 was considered statistically significant.
Conclusions
Our study indicates that in triage of repeated ASC-US/LSIL,
HPV mRNA testing is more specific and is more relevant in
clinical use than an HPV DNA test.
Supporting Information




Conceived and designed the experiments: SWS SF TJG ESM FES.
Performed the experiments: SWS SF TJG ESM FES. Analyzed the data:
SWS FES. Contributed reagents/materials/analysis tools: SWS SF TJG
ESM. Wrote the paper: SWS FES.
References
1. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, et al. (2012)
American Cancer Society, American Society for Colposcopy and Cervical
Pathology, and American Society for Clinical Pathology screening guidelines for
the prevention and early detection of cervical cancer. Am J Clin Pathol 137:
516–542.
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